Phase II study of S-1 plus oxaliplatin (130 mg/m2, every 3 weeks) for advanced gastric cancer

Trial Profile

Phase II study of S-1 plus oxaliplatin (130 mg/m2, every 3 weeks) for advanced gastric cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
    • 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top